Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq
Classical Hodgkin lymphoma (CHL) is characterized by a complex tumor microenvironment (TME) that supports disease progression. Although immune cell recruitment by Hodgkin and Reed-Sternberg (HRS) cells is well documented, the role of nonmalignant B cells in relapse remains unclear. Using single-cell RNA sequencing (scRNA-seq) on paired diagnostic and relapsed CHL samples, we identified distinct shifts in B-cell populations, particularly an enrichment of naïve B cells and a reduction of memory B cells in early-relapse CHL compared to late-relapse and newly diagnosed CHL. The enrichment of naïve B cells in early relapse biopsies was confirmed in independent validation cohorts using scRNA-seq and immunohistochemistry. Notably, naïve B cells in early-relapse samples exhibited high expression of LGALS9, an immunosuppressive gene encoding galectin-9, which binds to HAVCR2 (T-cell immunoglobulin and mucin domain-containing protein 3 [TIM-3]) on regulatory T cells (Tregs). Cell-cell interaction analysis revealed the importance of interactions between LGALS9+ naïve B cells and HAVCR2+ Tregs in the early-relapse setting. Spatial analysis by imaging mass cytometry confirmed close proximity of galectin-9-positive naïve B cells with TIM-3+ CD4+ T cells and HRS cells, pointing to their role in shaping an immunosuppressive niche. Our findings highlight a previously unrecognized population of galectin-9-positive naïve B cells with immunoregulatory potential in early-relapse CHL and provide new insights into the spatial and transcriptional architecture of the relapsed TME in CHL.
Authors
- Shinya Rai (ORCID: https://orcid.org/0000-0003-3929-9751)
- Aixiang Jiang (ORCID: https://orcid.org/0000-0002-6153-7595)
- Kerry J. Savage (ORCID: https://orcid.org/0000-0002-5835-9863)
- Stacy Hung
- David W. Scott (ORCID: https://orcid.org/0000-0002-0435-5947)
- Christian Steidl (ORCID: https://orcid.org/0000-0001-9842-9750)
- Adèle Telenius (ORCID: https://orcid.org/0000-0002-6901-5126)
- Luke O’Brien (ORCID: https://orcid.org/0000-0002-3893-009X)
- Alexander M. Xu (ORCID: https://orcid.org/0000-0003-4877-4358)
- Akil Abid Merchant (ORCID: https://orcid.org/0000-0001-7472-822X)
- Tomohiro Aoki (ORCID: https://orcid.org/0000-0001-6782-8361)
- Jan Delabie
- Lauren C. Chong (ORCID: https://orcid.org/0009-0007-8613-602X)
- Yifan Yin (ORCID: https://orcid.org/0009-0008-5382-478X)
Institutions
- Cedars-Sinai Medical Center (US)
- BC Cancer Agency (CA)
- University Health Network (CA)
- University of British Columbia (CA)
- University of Toronto (CA)
- Spinal Cord Injury BC (CA)
- Princess Margaret Cancer Centre (CA)
- Kindai University Hospital (JP)
- University of Maryland, College Park (US)
- Kindai University (JP)
Publication Details
- Journal
- Blood Advances
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1182/bloodadvances.2025017107
- Citations
- 1
- Primary Topic
- Galectins and Cancer Biology
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- AstraZeneca
- Uehara Memorial Foundation
- Genome Canada
- Regeneron Pharmaceuticals
- Veracyte
- Genome British Columbia
- Provincial Health Services Authority
- Eisai
- Terry Fox Research Institute
- Genentech
- Canadian Institutes of Health Research